Key Take away from Q Transcript :)With the resolution of outstanding litigation, our balance sheet is clean and we enjoy $18 million in cash at year-end with less than $3 million of debt and full ownership of our assets, including 3 production facilities. 2023 saw the continuation of MediPharm's turnaround and financial restructuring, positioning us for further growth in 2024 and beyond.
Better times ahead for LABS !! :) $$$